| 29.9288 2.059 (7.39%) | 01-14 11:19 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.99 |
1-year : | 38.82 |
| Resists | First : | 30.81 |
Second : | 33.23 |
| Pivot price | 29.72  |
|||
| Supports | First : | 26.88 | Second : | 22.37 |
| MAs | MA(5) : | 28.86 |
MA(20) : | 29.99 |
| MA(100) : | 32.22 |
MA(250) : | 34.1 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.7 |
| %K %D | K(14,3) : | 25.3 |
D(3) : | 21.8 |
| RSI | RSI(14): 47.7 |
|||
| 52-week | High : | 46.47 | Low : | 25.28 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ TGTX ] has closed below upper band by 49.6%. Bollinger Bands are 4.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.92 - 29.07 | 29.07 - 29.21 |
| Low: | 26.57 - 26.71 | 26.71 - 26.85 |
| Close: | 27.64 - 27.87 | 27.87 - 28.1 |
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and relapsing forms of multiple sclerosis; and Umbralisib, an oral inhibitor of PI3K-delta and CK1-epsilon for the treatment of CLL, marginal zone lymphoma, and follicular lymphoma. The company also develops Cosibelimab, a human monoclonal antibody of IgG1 subtype that binds to programmed death-ligand 1 (PD-L1) and blocks its interactions with PD-1 and B7.1 receptors; TG-1701 is an orally available and covalently-bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK compared to ibrutinib in in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. In addition, it has various licensed preclinical programs for BET, interleukin-1 receptor associated kinase-4, and GITR; and collaboration agreements with Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company has strategic alliances with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; and Rhizen Pharmaceuticals, S A. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Wed, 14 Jan 2026
Why TG Therapeutics Stock Is Moving Today - Benzinga
Wed, 14 Jan 2026
SG Americas Securities LLC Boosts Stock Holdings in TG Therapeutics, Inc. $TGTX - MarketBeat
Wed, 14 Jan 2026
TGTX Rallies 7% After Hours On Revenue Estimates Based On Strong Briumvi Demand Through 2026 - Menafn
Wed, 14 Jan 2026
Retail Traders Are Piling Into TG Therapeutics – What’s Driving The Chatter? - Stocktwits
Tue, 13 Jan 2026
TG Therapeutics (TGTX) Projects Strong Revenue Growth for 2026 - GuruFocus
Tue, 13 Jan 2026
TGTX: Briumvi's growth accelerates with new formulations, strong sales, and pivotal data expected in 2026 - TradingView — Track All Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 159 (M) |
| Held by Insiders | 1.4039e+008 (%) |
| Held by Institutions | 6.7 (%) |
| Shares Short | 25,220 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 2.76 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 50 |
| Profit Margin | 84.1 % |
| Operating Margin | 18.1 % |
| Return on Assets (ttm) | 7.9 % |
| Return on Equity (ttm) | 111.9 % |
| Qtrly Rev. Growth | 92.8 % |
| Gross Profit (p.s.) | 2.25836e+008 |
| Sales Per Share | 2.64627e+008 |
| EBITDA (p.s.) | 5.11592e+007 |
| Qtrly Earnings Growth | 12 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -70 (M) |
| PE Ratio | 10.73 |
| PEG Ratio | 0 |
| Price to Book value | 0.59 |
| Price to Sales | 0 |
| Price to Cash Flow | 14.03 |
| Dividend | 0 |
| Forward Dividend | 2.511e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|